BUSINESS● LOWSep 22 · Sep 22, 2026, 1:02 PM
Compass Therapeutics drops as FDA seeks additional trial for lead asset
Seeking Alpha Tech · north america
Compass Therapeutics' stock dropped after the FDA requested an additional trial for its lead asset.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS2m agoIn Kenya, the cancellation of the Vodafone-Safaricom deal threatens to weigh on the country's financesJeune AfriqueBUSINESS26m agoCLPS GAAP EPS of -$0.39, revenue of $87.1MSeeking Alpha Tech